Organon & Co. has entered into a commercialization agreement with Daiichi Sankyo Europe for Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland, and Norway. Under the terms of the agreement, Organon will distribute and promote Nilemdo® in these countries, while Daiichi Sankyo Europe will remain the marketing authorization holder. Nilemdo® is indicated for patients with high cholesterol and cardiovascular disease risk, particularly those who are statin-intolerant or cannot be treated effectively with statins.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260107056646) on January 08, 2026, and is solely responsible for the information contained therein.